1. P702 Clinical and biomarker remission is maintained after switch from monthly dosed intravenous to subcutaneous maintenance treatment with vedolizumab in Inflammatory Bowel Disease. (30th January 2023) Authors: Pintar, S; Hanžel, J; Smrekar, N; Koželj, M; Drobne, D; Kurent, T; Štabuc, B; Novak, G Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i834 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗